Triheptanoin clinical trials
Also written UX007 and Dojolvi.
How each study uses triheptanoin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the triheptanoin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Jun 2020 · DOJOLVI · NDA 213687 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2014 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 22
Ultragenyx Pharmaceutical Inc (6) · Institut National de la Santé Et de la Recherche Médicale, France (3) · Juan Pascual (3) · University of Texas Southwestern Medical Center (2) · Rigshospitalet, Denmark (2) · Jerry Vockley, MD, PhD (2) · The University of Queensland (1) · Areeg El-Gharbawy (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test triheptanoin, phase 3 first.
- Aug 2027A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODPhase 3 · Ultragenyx Pharmaceutical Inc
Studies
Open first, then newest update. How each study uses triheptanoin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 28
- Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) DeficiencyRecruitingPhase 1Jirair Krikor BedoyanNCT06340685Written as Triheptanoin
- A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODActive, not recruitingPhase 3Ultragenyx Pharmaceutical IncNCT05933200Written as Triheptanoin
- Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington DiseaseCompletedPhase 2Institut National de la Santé Et de la Recherche Médicale, FranceNCT01882062Written as Triheptanoin 1g/kg/day
- Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)WithdrawnPhase 2Jerry Vockley, MD, PhDNCT06067802Written as Triheptanoin
- Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)WithdrawnPhase 2Jerry Vockley, MD, PhDNCT07097311Written as Triheptanoin
- Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of ChildhoodCompletedPhase 2Institut National de la Santé Et de la Recherche Médicale, FranceNCT02408354Written as Triheptanoin
- Triheptanoin in Mc ArdleCompletedPhase 2Institut National de la Santé Et de la Recherche Médicale, FranceNCT02919631Written as Triheptanoin
- Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)CompletedPhase 2University of Texas Southwestern Medical CenterNCT03181399Written as Triheptanoin
- The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With GlycogenosesCompletedPhase 2Rigshospitalet, DenmarkNCT03642860Written as Triheptanoin
- Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1DCompletedPhase 2University of Texas Southwestern Medical CenterNCT03301532Written as Triheptanoin
- Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin StudiesCompletedPhase 2Ultragenyx Pharmaceutical IncNCT02214160Written as UX007
- Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of AnaplerosisCompletedPhase 2The University of QueenslandNCT04513002Written as Triheptanoin
- Treatment Development of Triheptanoin (G1D)CompletedPhase 1Juan PascualNCT03041363Written as Triheptanoin
- Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type ICompletedEarly Phase 1Areeg El-GharbawyNCT03665636Written as Triheptanoin
- A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)CompletedPhase 2Ultragenyx Pharmaceutical IncNCT01886378Written as UX007
- An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency SyndromeCompletedPhase 2Adrian LacyNCT02036853Written as Triheptanoin
- Treatment of Mitochondrial Dysfunction in Rett Syndrome With TriheptanoinStatus unknownPhase 2Center for Rare Neurological Diseases, Norcross, GANCT02696044Written as triheptanoin
- Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)CompletedPhase 2Ultragenyx Pharmaceutical IncNCT01993186Written as UX007
- Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)TerminatedPhase 3Ultragenyx Pharmaceutical IncNCT02960217Written as UX007
- Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)TerminatedPhase 2Ultragenyx Pharmaceutical IncNCT02599961Written as UX007
Codes
What other systems call triheptanoin · ClinicalTrials.gg INT005310
- MeSH (NLM) C531010triheptanoinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2P6O7CFW5KTRIHEPTANOINConfirmed FDA, NLM, Wikidata
- RxNorm 1313234Confirmed FDA, Wikidata
- Wikidata Q414576triheptanoinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166587TriheptanoinOne source FDA
- DrugBank DB11677One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C531010 | triheptanoin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2P6O7CFW5K | TRIHEPTANOIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1313234 | — | Confirmed FDA, Wikidata |
| Wikidata | Q414576 | triheptanoin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166587 | Triheptanoin | One source FDA |
| DrugBank | DB11677 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.